Working… Menu

WT1 Peptid Vaccination in Carcinomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00153608
Recruitment Status : Unknown
Verified September 2005 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
First Posted : September 12, 2005
Last Update Posted : February 14, 2006
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Condition or disease Intervention/treatment Phase
WT1 Expressing Carcinoma Biological: WT1 126-134 peptide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas
Study Start Date : April 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Wilms Tumor

Primary Outcome Measures :
  1. Clinical efficacy

Secondary Outcome Measures :
  1. Immune response
  2. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic cancer, no standard treatment option
  • Resected cancer with minimal residual disease, no standard treatment option
  • WT-1 expression
  • HLA-A2

Exclusion Criteria:

  • Concurrent chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00153608

Layout table for location contacts
Contact: Carmen Scheibenbogen, MD +49-30-8445-4576

Layout table for location information
Hem&Onc Charité CBF Recruiting
Berlin, Germany, 12200
Contact: Carmen Scheibenbogen, MD    +49-30-8445-4576   
Sponsors and Collaborators
Charite University, Berlin, Germany
Layout table for investigator information
Principal Investigator: Ulrich Keilholz, MD Charité CBF

Layout table for additonal information Identifier: NCT00153608     History of Changes
Other Study ID Numbers: HaemaCBFWT104
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: February 14, 2006
Last Verified: September 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs